Wells Fargo Starts Tectonic Therapeutics Inc. (TECX) at Overweight

Wells Fargo analyst Tiago Fauth initiates coverage on Tectonic Therapeutics Inc. (NASDAQ: TECX) with a Overweight rating and a price target of $55.00.

The analyst comments "What's the setup? Most drugs studied in Group 2 PH have been PAH vasodilators, which open narrowed blood vessels in the lungs but do not improve the ability of the left side of the heart to pump blood. TX45 is not a vasodilator but a relaxin, which has shown signs of improved left sided heart function across multiple Ph3 studies for NVS's serelaxin. TX45 not only improves upon serelaxin's short half life but targets an indication in which it could potentially lead to even greater efficacy."

For an analyst ratings summary and ratings history on Tectonic Therapeutics Inc. click here. For more ratings news on Tectonic Therapeutics Inc. click here.

Shares of Tectonic Therapeutics Inc. closed at $16.25 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• New Street Research Upgrades Micron Technology (MU) to Buy